Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary

Nuvation Bio

06/08/2026 14:31

Nuvation Bio Inc. NUVB.N reported a quarterly adjusted loss of 15 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -17 cents.  The mean expectation of ten analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -57 cents to -13 cents per share.
Revenue rose 555.6% to $31.69 million from a year ago; analysts expected $27.51 million. 
Nuvation Bio Inc.'s reported EPS for the quarter was a loss of 18 cents​.
The company reported a quarterly loss of $62.84 million.
Nuvation Bio Inc. shares had risen by 12.1% this quarter and lost 28.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.3% in the last three months.​ 
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Nuvation Bio Inc. is $12.00, about 46.9% above its last closing price of $6.37
This summary was machine generated from LSEG data August 6 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.19
-0.15
Beat
Mar. 31 2026 
0.01
0.01
Met
Dec. 31 2025 
-0.09
-0.11
Missed
Sep. 30 2025 
-0.17
-0.16
Beat